The goal of this exploratory pilot study is to generate early data needed for future validation studies of the automated BÜHLMANN BAT (Basophil activation test) assay. The main questions it aims to answer are:
Does the BAT assay use the optimal allergen concentrations for stimulation, and how do its preliminary cut-offs perform in a real-world clinical scenario?
Participants older than 1.5 years who are being evaluated for possible allergy sensitization will provide one additional blood tube during their routine blood draw as part of the regular medical care. The study involves only one visit and does not provide direct personal benefit.
Individuals with diagnosis of a hypersensitivity / allergy to one of the 6 allergens, established according to common clinical practice
Pregnant women
Children under the age of 18 months
Individuals under therapy with Omalizumab or Rituximab
Individuals with an allergic reaction less than two weeks before blood sample collection
Bühlmann Laboratories AG
Lead sponsor
Technical University Munchen
Collaborator